Breast Cancer
Conditions
Brief summary
This multicenter study in participants with HER2-positive eBC will investigate participants' pain and discomfort of SC trastuzumab (Herceptin) administered either via a single-use injection device (SID) or via vial for manual administration using a hand-held syringe (SC vial). In total, participants will obtain at least 18 cycles/1 year of trastuzumab (4 cycles of intravenous \[IV\] and 14 cycles of SC trastuzumab).
Interventions
DRUGTrastuzumab
Trastuzumab IV or SC will be administered as described.
DRUGPaclitaxel
Paclitaxel will be administered in accordance with local hospital practice.
DRUGDocetaxel
Docetaxel will be administered in accordance with local hospital practice.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Hormonal therapy allowed as per institutional guidelines * Left ventricular ejection fraction (LVEF) of greater than or equal to (\>/=) 55 percent (%) measured by echocardiography (ECHO) prior to first dose of trastuzumab * HER2-positive disease immunohistochemistry (IHC) 3+ or in-situ hybridization (ISH) positive as determined in a local laboratory that is experienced/certified in HER2-expression testing using an accurate and validated assay * Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast * No evidence of residual, locally recurrent or metastatic disease after completion of surgery and chemotherapy, or during concurrent chemotherapy (neo-adjuvant or adjuvant) * Participants who have completed all (neo)adjuvant treatment or participants after adjuvant chemotherapy with doxorubicin and cyclophosphamide (AC) to whom the 4 subsequent cycles of trastuzumab in combination with paclitaxel or docetaxel are indicated per local practice * Not more than 3 months should have elapsed since the last dose of adjuvant chemotherapy in case of subsequent treatment scheme
Exclusion criteria
* Previous neoadjuvant or adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent * History of other malignancy that can affect compliance with the protocol or interpretation of results. Participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma, and participants with other curatively treated malignancies who have been disease-free for at least 5 years, are eligible. Participants with previous ductal carcinoma in situ (DCIS) of the breast are also eligible for the study * Participants with severe dyspnea at rest or requiring supplementary oxygen therapy * Participants with other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness * Prior maximum cumulative dose of doxorubicin \>360 mg/m2 or maximum cumulative dose of epirubicin \>720 mg/m2 or equivalent * Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant valvular disease, evidence of transmural infarction on electrocardiogram (ECG), diagnosed poorly controlled hypertension * Known infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV) * Pregnant or lactating women * Concurrent enrollment in another clinical trial using an investigational anticancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment * Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin®, or the adhesive of the SC device, or a history of severe allergic or immunological reactions, e.g., difficult to control asthma * Inadequate bone marrow, hepatic, or renal function * Major surgical procedure or significant traumatic injury within 14 days prior to the first dose of study treatment or anticipated need for major surgery during the course of study treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Participant Pain as Measured on a 10 Centimeter (cm) Visual Analogue Scale | Week 13 up to Week 52 |
| Participant Discomfort as Measured on a 10 cm Visual Analogue Scale | Week 13 up to Week 52 |
Secondary
| Measure | Time frame |
|---|---|
| Healthcare Professional Perceived Time Savings With SC Trastuzumab as Assessed by HCPQ | Week 22 |
| Percentage of Participants With Adverse Events | Baseline up to approximately 3 years |
| Overall Survival | From first study treatment to death from any cause, assessed up to approximately 4.5 years |
| Disease-Free Survival, Assessed as per Institutional Practice or American Society of Clinical Oncology (ASCO) Adjuvant Follow-up Guidelines 2006 | From first study treatment to documented disease progression or death, assessed up to approximately 3 years |
| Number of Days on Trastuzumab Treatment | Week 1 up to Week 52 |
| Healthcare Professional Satisfaction With SC Formulation as Assessed by Health Care Professional Questionnaire (HCPQ) | Week 22 |
| Cumulative Dose of Trastuzumab | Week 1 up to Week 52 |
| Duration of Treatment | Week 1 up to Week 52 |
| Duration of Safety Observation | 28 days after last study treatment (up to Week 56) |
| Duration of Follow-Up | 25 months after last study treatment (up to 3 years) |
| Total Daily Dose of Trastuzumab | Week 1 up to Week 52 |
| Patient Satisfaction With SC Formulation as Assessed by Patients Satisfaction Questionnaire (PSQ) | Week 52 |
Countries
Belarus, Kazakhstan
Outcome results
None listed